Indaptus Therapeutics, Inc.

corporate_fare Company Profile

Indaptus Therapeutics, Inc.

INDP·NASDAQ·Life Sciences·CIK 0001857044

Indaptus Therapeutics, Inc. is a clinical biotechnology company focused on developing immunotherapy products to combat cancer and viral infections. Its primary product in development is Decoy20. This candidate is designed to be used either alone or in combination with other therapies to achieve lasting responses in various conditions. These include lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infections. Decoy20 is also being developed for the treatment of advanced solid tumors. The company, which was previously known as Intec Parent, Inc., adopted the name Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is based in New York, New York.

Indaptus Therapeutics, Inc. (NASDAQ:INDP) is a publicly traded company in the Life Sciences sector. Wiseek monitors INDP SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

Indaptus Registers 58.9M Shares for Resale — 44% of Outstanding (2026-08-17)
Indaptus Halts Decoy20, Pivots to Strategic Alternatives with $11.6M Cash (2026-08-13)
Indaptus Posts $1.8M Q2 Loss and Halts Decoy20 Program (2026-08-13)
Indaptus Seeks Shareholder Nod for 2026 Equity Plan and Board Elections as Cash Runs Low (2026-07-16)
CEO's Stake Diluted to 8.44% Following Recent Private Placement (2026-06-27)

Financial Snapshot

Fiscal year ended December 31, 2025

Net Income

-$20.85M

Diluted EPS

-$21.58

Op. Cash Flow

-$14.82M

Operating Income

-$19.83M

Cash & Equivalents

$8.51M

Debt / Equity

0.00×

Shares Outstanding

2.17M sh

Source: 10-K · filed 2026-03-17 · accession 0001493152-26-010585

Dilution Risk

Low risk

Filing-implied dilution signals for INDP, detected from its recent SEC filings · based on capital-structure filings through 2026-06-24.

2 shelf registrations

$12 Million Private Placement Completed · Significant Discount and Dilution

⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with I →

show_chartPrice Chart

Loading chart...

feed INDP - Latest Insights

Filing Type

Date Range

INDP

Aug 17, 2026, 5:00 PM EDT

Filing Type: S-3

Importance Score:

Indaptus Registers 58.9M Shares for Resale — 44% of Outstanding

Price at Filing: $1.00

Real-time Price: $0.940

Change: -$0.060 (-6%)

Market Cap: $125.248M

Sentiment: Negative

View Wiseek Article

INDP

Aug 13, 2026, 7:35 AM EDT

Filing Type: 10-Q

Importance Score:

Indaptus Halts Decoy20, Pivots to Strategic Alternatives with $11.6M Cash

Price at Filing: $1.01

Real-time Price: $0.940

Change: -$0.070 (-7%)

Market Cap: $125.248M

Sentiment: Negative

View Wiseek Article

INDP

Aug 13, 2026, 7:30 AM EDT

Filing Type: 8-K

Importance Score:

Indaptus Posts $1.8M Q2 Loss and Halts Decoy20 Program

Price at Filing: $1.01

Real-time Price: $0.940

Change: -$0.070 (-7%)

Market Cap: $125.248M

Sentiment: Negative

View Wiseek Article

INDP

Jul 16, 2026, 4:35 PM EDT

Filing Type: DEF 14A

Importance Score:

Indaptus Seeks Shareholder Nod for 2026 Equity Plan and Board Elections as Cash Runs Low

Price at Filing: $2.53

Real-time Price: $0.940

Change: -$1.59 (-63%)

Market Cap: $125.248M

Sentiment: Negative

View Wiseek Article

INDP

Jun 26, 2026, 8:00 PM EDT

Filing Type: SCHEDULE 13D/A

Importance Score:

CEO's Stake Diluted to 8.44% Following Recent Private Placement

Price at Filing: $3.41

Real-time Price: $0.940

Change: -$2.47 (-72%)

Market Cap: $125.248M

Sentiment: Neutral

View Wiseek Article

INDP

Jun 26, 2026, 8:00 PM EDT

Filing Type: SCHEDULE 13D/A

Importance Score:

Major Shareholder Yun Yao's Stake Diluted to 31.51% Following Recent Private Placement

Price at Filing: $3.41

Real-time Price: $0.940

Change: -$2.47 (-72%)

Market Cap: $125.248M

Sentiment: Neutral

View Wiseek Article

INDP

Jun 26, 2026, 5:21 PM EDT

Filing Type: S-3

Importance Score:

Selling Stockholders Register $72 Million in Common Stock for Resale

Price at Filing: $3.41

Real-time Price: $0.940

Change: -$2.47 (-72%)

Market Cap: $125.248M

Sentiment: Negative

View Wiseek Article

INDP

Jun 24, 2026, 4:03 PM EDT

Source: Wiseek News

Importance Score:

Indaptus Therapeutics Secures $12M in Deeply Discounted Offshore Private Placement at $0.60/Share

Price at Filing: $3.55

Real-time Price: $0.940

Change: -$2.61 (-74%)

Market Cap: $125.248M

Sentiment: Neutral

View Wiseek Article

INDP

Jun 24, 2026, 4:01 PM EDT

Filing Type: 8-K

Importance Score:

Indaptus Therapeutics Secures $12M in Deeply Discounted Private Placement

Price at Filing: $3.55

Real-time Price: $0.940

Change: -$2.61 (-74%)

Market Cap: $125.248M

Sentiment: Negative

View Wiseek Article

INDP

Jun 22, 2026, 5:25 PM EDT

Filing Type: PRE 14A

Importance Score:

Shareholders to Vote on Highly Dilutive $300M Capital Raise at Deep Discount

Price at Filing: $3.76

Real-time Price: $0.940

Change: -$2.82 (-75%)

Market Cap: $125.248M

Sentiment: Negative

View Wiseek Article

INDP

Jun 05, 2026, 4:30 PM EDT

Filing Type: 8-K

Importance Score:

Indaptus Therapeutics Completes Leadership Transition with Key Board and COO Resignations

Price at Filing: $3.31

Real-time Price: $0.940

Change: -$2.37 (-72%)

Market Cap: $125.248M

Sentiment: Neutral

View Wiseek Article

INDP

May 15, 2026, 8:15 AM EDT

Filing Type: 10-Q

Importance Score:

Indaptus Therapeutics Reports Critical Cash Shortage, Massive Dilution, and Halted Clinical Programs

Price at Filing: $1.75

Real-time Price: $0.940

Change: -$0.810 (-46%)

Market Cap: $125.248M

Sentiment: Negative

View Wiseek Article

INDP

May 15, 2026, 8:00 AM EDT

Filing Type: 8-K

Importance Score:

Indaptus Therapeutics Reports Critical Cash Shortage, Less Than One Month of Operating Funds Remaining

Price at Filing: $1.75

Real-time Price: $0.940

Change: -$0.810 (-46%)

Market Cap: $125.248M

Sentiment: Negative

View Wiseek Article

INDP

May 15, 2026, 7:00 AM EDT

Source: GlobeNewswire

Importance Score:

Cash Dwindles to $1.5M for Indaptus Therapeutics, Warns of Financing Uncertainty

Price at Filing: $1.75

Real-time Price: $0.940

Change: -$0.810 (-46%)

Market Cap: $125.248M

Sentiment: Negative

View Wiseek Article

INDP

Apr 29, 2026, 4:05 PM EDT

Filing Type: SCHEDULE 13D/A

Importance Score:

Major Investors Disband Group Formed During Recent Dilutive Financing

Price at Filing: $2.92

Real-time Price: $0.940

Change: -$1.98 (-68%)

Market Cap: $125.248M

Sentiment: Neutral

View Wiseek Article

INDP

Apr 22, 2026, 9:59 PM EDT

Filing Type: 8-K

Importance Score:

Indaptus Therapeutics Appoints Two Independent Directors, Bolstering Financial and IP Expertise

Price at Filing: $3.49

Real-time Price: $0.940

Change: -$2.55 (-73%)

Market Cap: $125.248M

Sentiment: Positive

View Wiseek Article

INDP

Apr 03, 2026, 12:00 PM EDT

Filing Type: 8-K

Importance Score:

Indaptus Therapeutics Appoints New CFO and Director Following Recent Change of Control

Price at Filing: $1.59

Real-time Price: $0.940

Change: -$0.650 (-41%)

Market Cap: $125.248M

Sentiment: Neutral

View Wiseek Article

INDP

Mar 30, 2026, 9:46 PM EDT

Filing Type: SCHEDULE 13D

Importance Score:

New Investor Group Acquires 98% of Indaptus Therapeutics, Appoints New CEO, Completing Change of Control

Price at Filing: $1.78

Real-time Price: $0.940

Change: -$0.840 (-47%)

Market Cap: $125.248M

Sentiment: Neutral

View Wiseek Article

INDP

Mar 24, 2026, 4:30 PM EDT

Filing Type: 8-K

Importance Score:

Indaptus Therapeutics Undergoes Near-Total Ownership Change, Appoints New CEO Amid $11.2M Preferred Stock Sale

Price at Filing: $1.68

Real-time Price: $0.940

Change: -$0.740 (-44%)

Market Cap: $125.248M

Sentiment: Negative

View Wiseek Article

INDP

Mar 24, 2026, 4:05 PM EDT

Filing Type: SCHEDULE 13D/A

Importance Score:

Co-CEO Sells Controlling Stake for $11.2M, Resigns Amidst Company Distress

Price at Filing: $1.67

Real-time Price: $0.940

Change: -$0.7301 (-44%)

Market Cap: $125.248M

Sentiment: Negative

View Wiseek Article

corporate_fare Company Profile